[go: up one dir, main page]

RU2016137668A - Новые производные каннабидиол-хинона - Google Patents

Новые производные каннабидиол-хинона Download PDF

Info

Publication number
RU2016137668A
RU2016137668A RU2016137668A RU2016137668A RU2016137668A RU 2016137668 A RU2016137668 A RU 2016137668A RU 2016137668 A RU2016137668 A RU 2016137668A RU 2016137668 A RU2016137668 A RU 2016137668A RU 2016137668 A RU2016137668 A RU 2016137668A
Authority
RU
Russia
Prior art keywords
compound
paragraphs
linear
group represented
branched group
Prior art date
Application number
RU2016137668A
Other languages
English (en)
Other versions
RU2016137668A3 (ru
RU2667504C2 (ru
Inventor
Джованни АППЕНДИНО
КАБЕЛЛО ДЕ АЛЬБА Мария Лус БЕЛЛИДО
БЛАНКО Эдуардо МУНЬОС
Original Assignee
Виваселл Биотекнолоджи Эспанья С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Виваселл Биотекнолоджи Эспанья С.Л. filed Critical Виваселл Биотекнолоджи Эспанья С.Л.
Publication of RU2016137668A3 publication Critical patent/RU2016137668A3/ru
Publication of RU2016137668A publication Critical patent/RU2016137668A/ru
Application granted granted Critical
Publication of RU2667504C2 publication Critical patent/RU2667504C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/28—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of non-condensed quinone rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/95—Esters of quinone carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (43)

1. Соединения формулы (I) или их производные
Figure 00000001
где R представляет собой атом углерода линейной или разветвленной группы, представленной: арильной, алкенильной, алкинильной, ацильной или алкоксикарбонильной группами; или где R представляет собой атом азота линейной или разветвленной группы, представленной: алкиламинной, ариламинной, алкениламинной или алкиниламинной группами.
2. Соединение по п. 1, выбранное из:
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
3. Композиции, содержащие соединение формулы (I)
Figure 00000016
где R представляет собой атом углерода линейной или разветвленной группы, представленной арильной, алкенильной, алкинильной, ацильной или алкоксикарбонильной группами; или где R представляет собой атом азота линейной или разветвленной группы, представленной: алкиламинной, ариламинной, алкениламинной или алкиниламинной группами
и, необязательно, по меньшей мере еще одно дополнительное активное соединение и/или по меньшей мере фармацевтически инертный ингредиент, такой как вспомогательное вещество и/или носитель.
4. Композиция по п. 3, отличающаяся тем, что соединение формулы (I) выбрано из:
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
5. Соединение по любому из пп. 1 или 2 для применения в качестве лекарственного средства.
6. Соединение по любому из пп. 1 или 2 для применения для лечения заболеваний, опосредованных PPRAg.
7. Соединение по п. 6 для применения для лечения заболевания, опосредованного PPRAg, выбранного из: атеросклероза, воспалительных заболеваний кишечника, ревматоидного артрита, фиброза печени, нефропатии, псориаза, заживления кожных ран, регенерации кожи, панкреатита, гастрита, нейродегенеративных расстройств, нейровоспалительных расстройств, склеродермии, рака, гипертонии, ожирения или диабета II типа.
8. Композиция по любому из пп. 3 или 4 для применения в качестве лекарственного средства.
9. Композиция по любому из пп. 3 или 4 для применения для лечения заболеваний, опосредованных PPARg.
10. Композиция по п. 9 для применения для лечения заболевания, опосредованного PPRAg, выбранного из: атеросклероза, воспалительных заболеваний кишечника, ревматоидного артрита, фиброза печени, нефропатии, псориаза, заживления кожных ран, регенерации кожи, панкреатита, гастрита, нейродегенеративных расстройств, нейровоспалительных расстройств, склеродермии, рака, гипертонии, ожирения или диабета II типа.
RU2016137668A 2014-04-16 2014-04-16 Новые производные каннабидиол-хинона RU2667504C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/057767 WO2015158381A1 (en) 2014-04-16 2014-04-16 Novel cannabidiol quinone derivatives

Publications (3)

Publication Number Publication Date
RU2016137668A3 RU2016137668A3 (ru) 2018-05-16
RU2016137668A true RU2016137668A (ru) 2018-05-16
RU2667504C2 RU2667504C2 (ru) 2018-09-21

Family

ID=50693623

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016137668A RU2667504C2 (ru) 2014-04-16 2014-04-16 Новые производные каннабидиол-хинона

Country Status (14)

Country Link
US (1) US9701618B2 (ru)
EP (1) EP3131874B1 (ru)
JP (1) JP6167248B2 (ru)
KR (1) KR102256398B1 (ru)
CN (1) CN106232570B (ru)
AU (1) AU2014390738B2 (ru)
BR (1) BR112016023902A2 (ru)
CA (1) CA2945867C (ru)
DK (1) DK3131874T3 (ru)
ES (1) ES2692693T3 (ru)
IL (1) IL248030B (ru)
MX (1) MX352386B (ru)
RU (1) RU2667504C2 (ru)
WO (1) WO2015158381A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL269623B2 (en) 2017-03-29 2025-05-01 Emerald Health Pharmaceuticals Inc Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity
CN106866419B (zh) * 2017-04-14 2020-01-10 石河子大学 一类萜酯化合物及其制备方法和用途
JP2020524679A (ja) * 2017-06-20 2020-08-20 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． カンナビジオール酸エステル組成物およびその使用
WO2020120637A1 (en) * 2018-12-11 2020-06-18 Emerald Health Pharmaceuticals Inc Cannabigerol quinone acid and salts thereof
CA3128939A1 (en) * 2019-02-06 2020-08-13 Emerald Health Pharmaceuticals Inc. Formulations of cannabidiol derivatives and their use as modulators of cannabinoid receptor type 2 (cb2)
AU2020235617B2 (en) * 2019-03-12 2025-06-05 Epm (Ip), Inc. Cannabinoid acid ester compositions and uses thereof
CN119632928A (zh) 2019-10-03 2025-03-18 耶路撒冷希伯来大学伊森姆研究发展有限公司 数个脂质体大麻素及其用途
WO2021139741A1 (zh) * 2020-01-08 2021-07-15 成都百裕制药股份有限公司 大麻二酚衍生物及其制备方法和在医药上的应用
CN113087743B (zh) 2020-01-08 2023-04-28 成都百裕制药股份有限公司 四氢大麻酚衍生物及其制备方法和在医药上的应用
US12545694B2 (en) 2020-01-08 2026-02-10 Chengdu Baiyu Pharmaceutical Co., Ltd. Cannabidiol derivatives, preparation method thereof and use thereof
WO2021159059A1 (en) * 2020-02-06 2021-08-12 Emerald Health Pharmaceuticals Inc. Composition and method for the treatment and prevention of cardiac, pulmonary, dermal, and renal fibrosis
WO2022137144A1 (en) * 2020-12-24 2022-06-30 Buzzelet Development And Technologies Ltd. Compositions comprising cannabinoid acid esters
CN114315585B (zh) 2022-03-04 2022-05-13 中国医学科学院药用植物研究所 一种羟戊苯甲酸双酯化合物及其制备方法和制药应用
CN116407529B (zh) * 2023-03-24 2024-05-10 南京医科大学 3-硝基-2,6-二羟基苯甲酸右崁醇或葑醇的酯的药物用途
WO2025168780A1 (en) * 2024-02-09 2025-08-14 Universidad de Córdoba Cannabinoid aminoquinone compounds as activators of ampk/sirtuin-1 pathway

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL159892A0 (en) 2004-01-15 2004-06-20 Yissum Res Dev Co Use of quinonoid derivatives of cannabinoids in the treatment of malignancies
US20090093521A1 (en) * 2005-06-14 2009-04-09 Maria Laura Bolognesi 2, 5-Bis-Diamine [1,4] Benzoquinone-Derivatives
WO2008107878A1 (en) * 2007-03-05 2008-09-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel quinonoid derivatives of cannabinoids and their use in the treatment of malignancies
WO2011117429A1 (es) 2010-03-26 2011-09-29 Vivacell Biotechnology España, S.L Derivados quinona de cannabinoides
US20130203715A1 (en) 2010-07-20 2013-08-08 Pulmatrix, Inc. Use of trp channel agonists to treat infections

Also Published As

Publication number Publication date
KR20160146765A (ko) 2016-12-21
EP3131874A1 (en) 2017-02-22
RU2016137668A3 (ru) 2018-05-16
AU2014390738A1 (en) 2016-10-27
MX2016013151A (es) 2017-02-02
BR112016023902A2 (pt) 2017-08-15
IL248030A0 (en) 2016-11-30
CN106232570A (zh) 2016-12-14
US20170044092A1 (en) 2017-02-16
IL248030B (en) 2019-10-31
MX352386B (es) 2017-11-22
ES2692693T3 (es) 2018-12-04
JP2017516753A (ja) 2017-06-22
KR102256398B1 (ko) 2021-05-27
JP6167248B2 (ja) 2017-07-19
CN106232570B (zh) 2018-08-07
RU2667504C2 (ru) 2018-09-21
AU2014390738B2 (en) 2019-05-02
WO2015158381A1 (en) 2015-10-22
US9701618B2 (en) 2017-07-11
DK3131874T3 (en) 2018-11-19
CA2945867C (en) 2021-11-09
EP3131874B1 (en) 2018-07-25
CA2945867A1 (en) 2015-10-22

Similar Documents

Publication Publication Date Title
RU2016137668A (ru) Новые производные каннабидиол-хинона
EA201890338A1 (ru) Оксадиазольные производные, пригодные в качестве ингибиторов hdac
EA201800064A1 (ru) 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
SA518391624B1 (ar) Ror- منظمات جاما
MX387345B (es) Compuestos arilo, heteroarilo, y heterocíclicos para el tratamiento de trastornos mediados por complemento.
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
EA201690094A1 (ru) Ингибиторы syk
EA202090486A3 (ru) Соединения для лечения спинальной мышечной атрофии
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EP4275748A3 (en) Compositions and methods for treating cns disorders
EA201591051A1 (ru) Ингибиторы erk и варианты их применения
EA201890086A1 (ru) 1,4-замещенные производные пиперидина
MX2021004492A (es) Composiciones para el tratamiento de trastornos del snc.
EA201891553A1 (ru) Ингибиторы syk
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
EA201891091A1 (ru) Соединения ингибитора jak киназы для лечения респираторного заболевания
UA114944C2 (uk) Піридинільні і конденсовані піридинільні похідні триазолону
EA202090987A8 (ru) Новые пролекарства на основе катехоламина для применения в лечении болезни паркинсона
EA201600636A1 (ru) 2-амино-6-метил-4,4а,5,6-тетрагидропирано[3,4-d][1,3]тиазин-8а(8н)-ил-1,3-тиазол-4-ил амиды
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant